0R91 Stock Overview
Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Belgium, Europe and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Mithra Pharmaceuticals SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.22 |
| 52 Week High | €3.85 |
| 52 Week Low | €0.20 |
| Beta | 0.45 |
| 1 Month Change | -2.82% |
| 3 Month Change | -80.18% |
| 1 Year Change | -92.44% |
| 3 Year Change | -99.11% |
| 5 Year Change | -99.14% |
| Change since IPO | -97.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0R91 | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -0.9% | -1.2% | -0.7% |
| 1Y | -92.4% | -5.0% | -1.8% |
Return vs Industry: 0R91 underperformed the UK Pharmaceuticals industry which returned -5% over the past year.
Return vs Market: 0R91 underperformed the UK Market which returned -1.8% over the past year.
Price Volatility
| 0R91 volatility | |
|---|---|
| 0R91 Average Weekly Movement | 18.1% |
| Pharmaceuticals Industry Average Movement | 8.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0R91's share price has been volatile over the past 3 months.
Volatility Over Time: 0R91's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 270 | Christophe Marechal | www.mithra.com |
Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Belgium, Europe and internationally. Its development candidates include Estelle, a combined oral contraceptive that has completed phase III clinical trial; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment; and products for neuroprotection and wound healing. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a tablet composed of tibolone and a synthetic steroid used for hormone therapy in menopause; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications.
Mithra Pharmaceuticals SA Fundamentals Summary
| 0R91 fundamental statistics | |
|---|---|
| Market cap | €15.48m |
| Earnings (TTM) | -€173.50m |
| Revenue (TTM) | €40.16m |
0.4x
P/S Ratio-0.1x
P/E RatioIs 0R91 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0R91 income statement (TTM) | |
|---|---|
| Revenue | €40.16m |
| Cost of Revenue | €21.95m |
| Gross Profit | €18.21m |
| Other Expenses | €191.71m |
| Earnings | -€173.50m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | -2.51 |
| Gross Margin | 45.34% |
| Net Profit Margin | -432.08% |
| Debt/Equity Ratio | -258.9% |
How did 0R91 perform over the long term?
See historical performance and comparison